Straits Times Index
3,301.31 +4.42 (+0.13%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,479.80 +272.67 (+1.50%) FTSE 100
8,196.85 +24.70 (+0.30%) Bitcoin USD
59,186.12 +1,499.64 (+2.60%) CMC Crypto 200
1,295.26 +18.28 (+1.43%)
Swedish Orphan Biovitrum AB (B6E.BE)
| Previous close | 23.86 |
| Open | 23.96 |
| Bid | 24.12 x 0 |
| Ask | 24.14 x 0 |
| Day's range | 23.96 - 23.96 |
| 52-week range | 16.24 - 25.90 |
| Volume | |
| Avg. volume | 2 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. Efanesoctocog alfa is a once-weekly and high-sustained factor VIII replacement therapy for patients of all ages and any disease severity.
- PR Newswire
Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
- PR Newswire
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be held on Tuesday, 14 May 2024 at 15.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.
